Integrating biomarkers in clinical trials

Marc Buyse; Stefan Michiels; Daniel J. Sargent; Axel Grothey; Alastair Matheson; Aimery De Gramont

doi:10.1586/erm.10.120

Integrating biomarkers in clinical trials

Marc Buyse, Stefan Michiels, Daniel J. Sargent, Axel Grothey, Alastair Matheson, Aimery De Gramont

Research output: Contribution to journal › Review article › peer-review

107 Citations (Scopus)

Abstract

Biomarkers have a growing role in clinical trials. With the advent of the targeted therapy era, molecular biomarkers in particular are becoming increasingly important within both clinical research and clinical practice. This article focuses on biomarkers that anticipate the prognosis of individual patients ('prognostic' biomarkers) and on biomarkers that predict how individual patients will respond to specific treatments ('predictive' biomarkers, also called 'effect modifiers'). Specific Phase II and III clinical trial designs are discussed in detail for their ability to validate the biomarker and/or to establish the effect of an experimental therapy in patient populations defined by the presence or absence of the biomarker. Contemporary biomarker-based clinical trials in oncology are used as examples.

Original language	English
Pages (from-to)	171-182
Number of pages	12
Journal	Expert Review of Molecular Diagnostics
Volume	11
Issue number	2
DOIs	https://doi.org/10.1586/erm.10.120
Publication status	Published - 1 Mar 2011
Externally published	Yes

Keywords

biomarker
predictive marker
prognostic marker
trial design
validation

Access to Document

10.1586/erm.10.120

Cite this

@article{7f2c889c0c5e470d82c399e653d5574a,

title = "Integrating biomarkers in clinical trials",

abstract = "Biomarkers have a growing role in clinical trials. With the advent of the targeted therapy era, molecular biomarkers in particular are becoming increasingly important within both clinical research and clinical practice. This article focuses on biomarkers that anticipate the prognosis of individual patients ('prognostic' biomarkers) and on biomarkers that predict how individual patients will respond to specific treatments ('predictive' biomarkers, also called 'effect modifiers'). Specific Phase II and III clinical trial designs are discussed in detail for their ability to validate the biomarker and/or to establish the effect of an experimental therapy in patient populations defined by the presence or absence of the biomarker. Contemporary biomarker-based clinical trials in oncology are used as examples.",

keywords = "biomarker, predictive marker, prognostic marker, trial design, validation",

author = "Marc Buyse and Stefan Michiels and Sargent, {Daniel J.} and Axel Grothey and Alastair Matheson and {De Gramont}, Aimery",

year = "2011",

month = mar,

day = "1",

doi = "10.1586/erm.10.120",

language = "English",

volume = "11",

pages = "171--182",

journal = "Expert Review of Molecular Diagnostics",

issn = "1473-7159",

number = "2",

}

TY - JOUR

T1 - Integrating biomarkers in clinical trials

AU - Buyse, Marc

AU - Michiels, Stefan

AU - Sargent, Daniel J.

AU - Grothey, Axel

AU - Matheson, Alastair

AU - De Gramont, Aimery

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Biomarkers have a growing role in clinical trials. With the advent of the targeted therapy era, molecular biomarkers in particular are becoming increasingly important within both clinical research and clinical practice. This article focuses on biomarkers that anticipate the prognosis of individual patients ('prognostic' biomarkers) and on biomarkers that predict how individual patients will respond to specific treatments ('predictive' biomarkers, also called 'effect modifiers'). Specific Phase II and III clinical trial designs are discussed in detail for their ability to validate the biomarker and/or to establish the effect of an experimental therapy in patient populations defined by the presence or absence of the biomarker. Contemporary biomarker-based clinical trials in oncology are used as examples.

AB - Biomarkers have a growing role in clinical trials. With the advent of the targeted therapy era, molecular biomarkers in particular are becoming increasingly important within both clinical research and clinical practice. This article focuses on biomarkers that anticipate the prognosis of individual patients ('prognostic' biomarkers) and on biomarkers that predict how individual patients will respond to specific treatments ('predictive' biomarkers, also called 'effect modifiers'). Specific Phase II and III clinical trial designs are discussed in detail for their ability to validate the biomarker and/or to establish the effect of an experimental therapy in patient populations defined by the presence or absence of the biomarker. Contemporary biomarker-based clinical trials in oncology are used as examples.

KW - biomarker

KW - predictive marker

KW - prognostic marker

KW - trial design

KW - validation

UR - http://www.scopus.com/inward/record.url?scp=79952928150&partnerID=8YFLogxK

U2 - 10.1586/erm.10.120

DO - 10.1586/erm.10.120

M3 - Review article

C2 - 21405968

AN - SCOPUS:79952928150

SN - 1473-7159

VL - 11

SP - 171

EP - 182

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

IS - 2

ER -

Integrating biomarkers in clinical trials

Abstract

Keywords

Access to Document

Other files and links

Cite this